Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Oruka Therapeutics, Inc. has 61.07M shares outstanding.

As of June 30, 2026, Oruka Therapeutics, Inc. maintains a current ratio of 38.51, meaning it holds 38.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Oruka Therapeutics, Inc. posted a negative return on equity (ROE) of -18.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.76, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Oruka Therapeutics, Inc. generated - - in revenue and converted that into -116.32M in net income, yielding earnings per share of -2.14. EBITDA reached -71.84M, while operating income came in at -135.74M.

As of June 30, 2026, Oruka Therapeutics, Inc. holds 764.63M in cash and equivalents against 2.23M in total debt, resulting in a net debt position of -234.99M. Total book value stands at 973.00M, with working capital of 754.15M providing operational flexibility.

Oruka Therapeutics, Inc. produced -88.33M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -205,695.50 in capital expenditures, free cash flow totaled -88.54M - equivalent to -1.63 per share.

Oruka Therapeutics, Inc.'s most recent stock split took place on September 3, 2024 with a 12:1 split ratio.